Sarcoma vaccine (MabVax/MSKCC)

N/A

Report date: 2022/09/01 20:01:19

Base Information

Drug NameSarcoma vaccine (MabVax/MSKCC)
Drug Alias NameMV-Sarc
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsGanglioside GD3 inhibitorsGM2(ganglioside M2) inhibitors +[4] 
TargetsGanglioside GD3Disialoganglioside GD2GM2(ganglioside M2)
Therapy Area/IndicationsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterMabvax Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMabvax Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSarcoma

Other Information

ATC CodeN/A
Related LinksN/A